Similarly, V-raf murine sarcoma viral oncogene homologue B1 (BRAF) and mitogen-activated protein kinase (MEK) inhibitors were recently approved with a tumour-agnostic indication for unresectable or metastatic solid tumours harbouring the BRAF V600E mutation (Gouda and Subbiah, 2023). The gene discussed is BRAF; the disease is neoplasm.